STOCK TITAN

Editas Medicine Inc - EDIT STOCK NEWS

Welcome to our dedicated news page for Editas Medicine (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Editas Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Editas Medicine's position in the market.

Rhea-AI Summary
Editas Medicine, Inc. will host a conference call and webcast on November 3, 2023, to discuss Q3 2023 results and provide a corporate update. The company will also participate in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
conferences earnings
-
Rhea-AI Summary
Editas Medicine grants inducement award to Chief Commercial and Strategy Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary
Editas Medicine appoints Caren Deardorf as Chief Commercial and Strategy Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.49%
Tags
management
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
Rhea-AI Summary
Editas Medicine reports financial results for Q2 2023 and provides business updates. The company remains on track with its EDIT-301 program for SCD and TDT, and plans to provide clinical updates by year-end. Editas has strengthened its executive team with the appointment of a new CFO and CSO. The company is also advancing its internal manufacturing capabilities. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $480.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management
Rhea-AI Summary
Editas Medicine, Inc. announces the pricing of an underwritten offering of 12,500,000 shares of its common stock at $10.00 per share, with expected gross proceeds of approximately $125 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.32%
Tags
Editas Medicine Inc

Nasdaq:EDIT

EDIT Rankings

EDIT Stock Data

508.06M
75.99M
0.91%
80.47%
20%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About EDIT

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.